Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | Biomarker | disease | BEFREE | Loss of klotho might be a consequence of cyst growth and constrain the phosphaturic effect of FGF23 in most patients with ADPKD. | 22193235 | 2012 | ||||
|
0.070 | AlteredExpression | disease | BEFREE | The serum FGF23 levels were significantly higher and soluble Klotho levels significantly lower in the ADPKD group than in the non-diabetic CKD group matched for eGFR, and these findings may be associated with resistance of renal phosphate excretion. | 27450645 | 2017 | ||||
|
0.070 | AlteredExpression | disease | BEFREE | This study shows increased fibroblast growth factor-23 levels in patients with autosomal dominant polycystic kidney disease which is in harmony with the general trend in patients with chronic kidney disease of other aetiologies, but, unlike them, also a significant increase in serum soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease suggesting an aberrant production or a decreased clearance of α-Klotho molecule. | 27733443 | 2017 | ||||
|
0.070 | Biomarker | disease | BEFREE | Higher serum fibroblast growth factor 23 concentration was associated with kidney function decline, height-adjusted total kidney volume percentage increase, and death in patients with autosomal dominant polycystic kidney disease. | 28705885 | 2017 | ||||
|
0.070 | Biomarker | disease | BEFREE | We found that FGF23 plasma concentration independently correlated with the severity of cystic liver disease in ADPKD. | 29618028 | 2018 | ||||
|
0.070 | Biomarker | disease | BEFREE | The Association of Fibroblast Growth Factor 23 with Arterial Stiffness and Atherosclerosis in Patients with Autosomal Dominant Polycystic Kidney Disease. | 30064143 | 2018 | ||||
|
0.070 | Biomarker | disease | BEFREE | Laboratory parameters of bone mineral metabolism (fibroblast growth factor 23 and sclerostin), bone turnover markers (bone alkaline phosphatase, tartrate-resistant acid phosphatase 5b) and bone mineral density (BMD, by dual energy x-ray absorptiometry, DXA) were assessed in 518 patients with ESRD, including 99 with ADPKD. | 30665572 | 2019 |